Chris Nave

BOARD REPRESENTATIVE

Managing Director
Brandon Capital Partners
Level 9, 31 Queen Street
Melbourne VIC 3000

Chris is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund.

Chris previously was Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He was responsible for the commercialisation of technologies developed at the Baker and the Alfred Hospital, including the management of local and international spinout companies.

He is currently a Director of OccuRx Pty Ltd, Osprey Medical Inc., PolyActiva Pty Ltd, Global Kinetics Corporation, EBR Systems, QueOncology Pty Ltd, Azura Ophthalmics, Certa Therapeutics and Cardiora Pty Ltd. Chris was Chairperson of Fibrotech Therapeutics at the time of its successful sale to Shire and a Director of Spinifex Pharmaceuticals at the time of its sale to Novartis.